| 1S9 Stock | | | EUR 0.83 0.05 5.68% |
Executive
Carlo Tanzi is Head of Investor Relations and Corporate Communications of Seres Therapeutics since 2017.
| Tenure | 7 years |
| Phone | 617 945 9626 |
| Web | https://www.serestherapeutics.com |
Seres Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.4018) % which means that it has lost $0.4018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(1.9017) %, meaning that it generated substantial loss on money invested by shareholders. Seres Therapeutics' management efficiency ratios could be used to measure how well Seres Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Seres Therapeutics has accumulated 24.64
M in total debt with debt to equity ratio
(D/E) of 0.23, which may suggest the company is not taking enough advantage from borrowing. Seres Therapeutics has a current ratio of 5.67, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Seres Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Seres Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seres Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seres to invest in growth at high rates of return. When we think about Seres Therapeutics' use of debt, we should always consider it together with cash and equity.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. SERES THERAPEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 155 people. Seres Therapeutics (1S9) is traded on Frankfurt Exchange in Germany and employs 333 people.
Management Performance
Seres Therapeutics Leadership Team
Elected by the shareholders, the Seres Therapeutics' board of directors comprises two types of representatives: Seres Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seres. The board's role is to monitor Seres Therapeutics' management team and ensure that shareholders' interests are well served. Seres Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seres Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeff York, VP HR | |
| SPHR SHRMSCP, Ex Officer | |
| Thomas DesRosier, Chief Legal Officer, Executive Vice President and Secretary | |
| David Ege, Executive Vice President, Chief Technology Officer | |
| Dennis Ausiello, Independent Director | |
| Willard Dere, Independent Director | |
| Eric Shaff, President, Chief Executive Officer, Director | |
| David MBA, CFO VP | |
| Carlo Tanzi, Head of Investor Relations and Corporate Communications | |
| Kristin Ainsworth, Sr Communications | |
| Marcus Chapman, Senior Vice President - Finance and Principal Financial and Accounting Officer | |
| JD Esq, Exec Officer | |
| Richard Kender, Independent Director | |
| Lisa MD, Ex Officer | |
| Meryl Zausner, Independent Director | |
| Stephen Berenson, Independent Chairman of the Board | |
| John Aunins, Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer | |
| Matthew Henn, Executive Vice President Chief Scientific Officer | |
| Jayne Gansler, Chief People Officer, Executive Vice President | |
| Kurt Graves, Independent Director | |
| Eric MBA, CEO Pres | |
| Gregory Behar, Independent Director | |
| Lisa Moltke, Executive Vice President Chief Medical Officer | |
| Paul Biondi, Independent Director | |
| Terri Young, Executive Vice President Chief Commercial and Strategy Officer | |
Seres Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seres Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Seres Stock
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics'
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For more detail on how to invest in Seres Stock please use our
How to Invest in Seres Therapeutics guide.
You can also try the
Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.